Modelling undiagnosed muscular dystrophies using patients s stem cells
Neuromuscular Diseases (NMDs), affecting both children and adults with a prevalence of 1 in a 1000 people, form a large and heterogeneous group of genetic diseases causing progressive degeneration of skeletal muscles. Most NMDs re...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MAGIC
Next-generation models and genetic therapies for rare neurom...
7M€
Cerrado
PRE2019-090622
COMPRENSION DE LAS CAUSAS MOLECULARES DE LA ATROFIA MUSCULAR...
98K€
Cerrado
BIND
Brain Involvement iN Dystrophinopathies
7M€
Cerrado
RYC-2013-14779
Generation of new therapy strategies for muscular dystrophie...
309K€
Cerrado
RTI2018-094599-B-I00
COMPRENSION DE LAS CAUSAS MOLECULARES DE LA ATROFIA MUSCULAR...
224K€
Cerrado
PTQ-15-08062
Estudio de las causas genéticas de las enfermedades del neur...
87K€
Cerrado
Información proyecto MUMDUPSC
Duración del proyecto: 29 meses
Fecha Inicio: 2021-04-13
Fecha Fin: 2023-09-14
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Neuromuscular Diseases (NMDs), affecting both children and adults with a prevalence of 1 in a 1000 people, form a large and heterogeneous group of genetic diseases causing progressive degeneration of skeletal muscles. Most NMDs result in chronic long-term disability imposing a significant burden on patients, families and public health care. In many cases, patients die prematurely from respiratory, and in some cases cardiac, muscle impairment. There are more than 200 NMDs, including over 30 types of Muscular Dystrophy (MD) which results from the mutation of genes controlling muscle functions and structures. The classification of MDs is not fixed but evolves with the constant discovery of new genes/mutations responsible for these diseases. Despite more than 40 genes involved in MDs have already been identified many genes are still to be discovered. In Europe, thousand patients with MD are currently without molecular diagnosis. Delayed or inaccurate diagnoses postpone the adequate care and may have irreversible consequences for the patients. MUMDUPSC aims combining descriptive clinical diagnosis, genomics and disease modelling from patients’ induced Pluripotent Stem Cells (hiPSC) to identify both molecular mechanisms and genetic mutations underlying undiagnosed muscular dystrophies (UMDs). Specifically, I propose to generate hiPSC from selected UMD patients and investigate their transcription profile during skeletal muscle differentiation compared to control cells (unaffected or affected with known MDs). By identifying, for the first time, DEGs specifically modulated in UMDs, MUMDUPSC will reveal the genes and pathways specifically contributing to the diseases. It will represent a proof of concept for the classification of unlabeled muscle pathologies and, in the long term, will provide innovative leads for the diagnosis and the treatment of these debilitating diseases.